Session Chair Profile
Ph.D., CSO, OX2 Therapeutics and Assistant Professor, University of Minnesota
Dr. Olin is an Assistant Professor in the Department of Pediatrics, Division of Hematology/Oncology. Dr. Olin graduated from the University of Minnesota, Duluth, in 1995 with a BS in biochemistry and Hydrogeology, a BA in chemistry. After graduating, he worked in industry for 5 years before returning to the U of M to complete his PhD in Veterinary Medicine (Infectious Disease) in 2005. From 2006-2008 Dr. Olin did a postdoctoral fellowship studying the effects of opioids on tuberculosis meningitis, and from 2008-2011 he did a second post doctoral fellowship in brain tumor immunotherapy. Dr. Olin joined the Department of Pediatrics Faculty as an Assistant Professor in 2011. In 2016, Dr. Olin opened a pharmaceutical company OX2 Therapeutics, to raise capital allowing him to develop and test his novel CD200 inhibitor.
Immunotherapy Showcase: OX2 Therapeutics
OX2 Therapeutics was established in 2016 in order to make a transformative impact in the treatment of Primary Brain Tumors.
Targeting The CD200 Immune Checkpoint For Cancer Immunotherapy
We are targeting the unique CD200checkpoint, which negatively regulated the immune system the secretion of the immunosuppressive CD200 from tumors and the upregulation of CD200 in tumor-associated vascular endothelial cells, creating an immunological barricade around the tumor microenvironment.